Accesses to anti-amyloid disease-modifying therapy impact awareness about cardiac amyloidosis and clinical practice: insights from an international survey

Back

HFA Premium Access

Accesses to anti-amyloid disease-modifying therapy impact awareness about cardiac amyloidosis and clinical practice: insights from an international survey

Session: Chronic heart failure - treatment 9

Topic: Pharmacotherapy

Speaker: Doctor D. Niederseer (Davos Wolfgang, CH)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor David Niederseer

Hochgebirgsklinik Davos, Davos Wolfgang (Switzerland)

6 presentations

0 follower

7 more presentations in this session

Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.

Speaker: Doctor M. Sweeney (London, GB)

Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.

Speaker: Miss H. Hauksdottir (Reykjavik, IS)

The effect of an incentive billing code on heart failure management in primary care: a population-based study

Speaker: Doctor S. Zhou (Toronto, CA)

A novel dual-action insulin secreting and natriuretic peptide, CRRL 101, a potential therapy for diabetic cardiomyopathy

Speaker: Doctor I. Isaia (Rochester, US)

Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.

Speaker: Doctor I. Fumarulo (Rome, IT)

Access the full session

Chronic heart failure - treatment 9

Speakers: Doctor D. Niederseer, Doctor M. Sweeney, Miss H. Hauksdottir, Doctor S. Zhou, Doctor I. Isaia...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources